Advertisement
Brief Report| Volume 25, ISSUE 3, 100357, March 2023

Hospital-level variation in genetic testing in children’s hospitals’ neonatal intensive care units from 2016 to 2021

Published:December 12, 2022DOI:https://doi.org/10.1016/j.gim.2022.12.004

      Abstract

      Purpose

      This study aimed to examine variation in genetic testing between neonatal intensive care units (NICUs) across hospitals over time.

      Methods

      We performed a multicenter large-scale retrospective cohort study using NICU discharge data from the Pediatric Hospital Information System database between 2016 and 2021. We analyzed the variation in the percentage of NICU patients who had any genetic testing across hospitals and over time. We used a multivariable multilevel logistic regression model to investigate the potential association between patient characteristics and genetic testing.

      Results

      The final analysis included 207,228 neonates from 38 hospitals. Overall, 13% of patients had at least 1 genetic test sent, although this varied from 4% to 50% across hospitals. Over the study period, the proportion of patients tested increased, with the increase disproportionately borne by hospitals already testing high proportions of patients. On average, patients who received genetic testing had higher illness severity. Controlling for severity, however, only minimally reduced the degree of hospital-level variation in genetic testing.

      Conclusion

      The percentage of NICU patients who undergo genetic testing varies among hospitals and increasingly so over time. Variation is largely unexplained by differences in severity between hospitals. The degree of variation suggests that clearer guidelines for NICU genetic testing are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ACMG Member Login

      Are you an ACMG Member? Sign in for online access.

      Subscribe:

      Subscribe to Genetics in Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Powis Z.
        • Farwell Hagman K.D.
        • Speare V.
        • et al.
        Exome sequencing in neonates: diagnostic rates, characteristics, and time to diagnosis.
        Genet Med. 2018; 20: 1468-1471https://doi.org/10.1038/gim.2018.11
        • Friedman J.M.
        • Bombard Y.
        • Cornel M.C.
        • et al.
        Genome-wide sequencing in acutely ill infants: genomic medicine’s critical application?.
        Genet Med. 2019; 21: 498-504https://doi.org/10.1038/s41436-018-0055-z
        • Swaggart K.A.
        • Swarr D.T.
        • Tolusso L.K.
        • He H.
        • Dawson D.B.
        • Suhrie K.R.
        Making a genetic diagnosis in a level IV neonatal intensive care unit population: who, when, how, and at what cost?.
        J Pediatr. 2019; 213: 211-217.e4https://doi.org/10.1016/j.jpeds.2019.05.054
        • Gonzaludo N.
        • Belmont J.W.
        • Gainullin V.G.
        • Taft R.J.
        Estimating the burden and economic impact of pediatric genetic disease.
        Genet Med. 2019; 21 (Published correction appears in Genet Med. 2019;21(9):2161): 1781-1789https://doi.org/10.1038/s41436-018-0398-5
        • Costa T.
        • Scriver C.R.
        • Childs B.
        The effect of Mendelian disease on human health: a measurement.
        Am J Med Genet. 1985; 21: 231-242https://doi.org/10.1002/ajmg.1320210205
        • Wojcik M.H.
        • Schwartz T.S.
        • Thiele K.E.
        • et al.
        Infant mortality: the contribution of genetic disorders.
        J Perinatol. 2019; 39: 1611-1619https://doi.org/10.1038/s41372-019-0451-5
        • Krantz I.D.
        • Medne L.
        • et al.
        • NICUSeq Study Group
        Effect of whole-genome sequencing on the clinical management of acutely ill infants with suspected genetic disease: a randomized clinical trial.
        JAMA Pediatr. 2021; 175 (Published correction appears in JAMA Pediatr. 2021;175(12):1295): 1218-1226https://doi.org/10.1001/jamapediatrics.2021.3496
        • Callahan K.P.
        • Flibotte J.
        • Skraban C.
        • et al.
        Influence of genetic information on neonatologists’ decisions: a psychological experiment.
        Pediatrics. 2022; 149e2021052130https://doi.org/10.1542/peds.2021-052130
        • Char D.S.
        • Lee S.S.J.
        • Magnus D.
        • Cho M.
        Anticipating uncertainty and irrevocable decisions: provider perspectives on implementing whole-genome sequencing in critically ill children with heart disease.
        Genet Med. 2018; 20: 1455-1461https://doi.org/10.1038/gim.2018.25
        • Janvier A.
        • Barrington K.
        • Lantos J.
        Next generation sequencing in neonatology: what does it mean for the next generation?.
        Hum Genet. 2022; 141: 1027-1034https://doi.org/10.1007/s00439-022-02438-9
        • Phillips K.A.
        • Deverka P.A.
        • Hooker G.W.
        • Douglas M.P.
        Genetic test availability and spending: where are we now? Where are we going?.
        Health Aff (Millwood). 2018; 37: 710-716https://doi.org/10.1377/hlthaff.2017.1427
        • Rady Children’s Institute Genomic Medicine
        Blue shield of California becomes first health plan in U.S. to cover cost of rapid whole genome sequencing for critically ill children. Rady Children’s Institute Genomic Medicine.
        (Published March 13, 2020)
        • Mason M.J.
        • Moran J.W.
        Understanding and controlling variation in public health.
        J Public Health Manag Pract. 2012; 18: 74-78https://doi.org/10.1097/PHH.0b013e318233d5eb
        • Fisher E.S.
        • Wennberg D.E.
        • Stukel T.A.
        • Gottlieb D.J.
        • Lucas F.L.
        • Pinder E.L.
        The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care.
        Ann Intern Med. 2003; 138: 288-298https://doi.org/10.7326/0003-4819-138-4-200302180-00007
        • Feudtner C.
        • Feinstein J.A.
        • Zhong W.
        • Hall M.
        • Dai D.
        Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation.
        BMC Pediatr. 2014; 14: 199https://doi.org/10.1186/1471-2431-14-199
        • Lynch J.A.
        • Berse B.
        • Dotson W.D.
        • Khoury M.J.
        • Coomer N.
        • Kautter J.
        Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data.
        Genet Med. 2017; 19: 890-899https://doi.org/10.1038/gim.2016.209
        • Delamater P.L.
        • Messina J.P.
        • Grady S.C.
        • WinklerPrins V.
        • Shortridge A.M.
        Do more hospital beds lead to higher hospitalization rates? A spatial examination of Roemer’s law.
        PLoS One. 2013; 8e54900https://doi.org/10.1371/journal.pone.0054900
        • Callahan K.P.
        • Flibotte J.
        • Skraban C.
        • et al.
        How neonatologists use genetic testing: findings from a national survey.
        J Perinatol. 2022; 42: 260-261https://doi.org/10.1038/s41372-021-01283-4